Head-to-head · WeighScore
Eve vs Meto
The verdict
Eve takes it — 66/100 to 62/100.
Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eve | Meto |
|---|---|---|
| WeighScore | 66/100 | 62/100 |
| Grade | C | C |
| Scorecard rank | #210 | #281 |
| Semaglutide | $195/mo (compounded) | Not disclosed |
| Tirzepatide | $195/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #210 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Graded #281 · C
Strengths
- Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
- Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
- Matches patients with endocrinologists and obesity medicine specialists within minutes
- Offers compounded semaglutide and tirzepatide with board-certified physician oversight
- Handles all prior-auth paperwork; provider location pages exist for all 50 US states
Where it loses points
- Medication pricing fully gated behind quiz — no public cash price for sema or tirz
- Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
- No LegitScript certification or named compounding pharmacy found on any public page
- Company leadership and clinical team not disclosed publicly
- Self-pay cash pricing exists per site copy but is not published anywhere
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.